Optimizing chemoradiation in locally advanced non-small-cell lung cancer

ONCOLOGY

Volumn 15, Issue 3 SUPPL. 6, 2001, Pages 43-45

  Curran Jr , Walter J ^a   Choy, Hak ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; HUMANS; LUNG NEOPLASMS;

EID: 0035291328     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Carmichael J, Possinger K, Phillip P, et al: Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 13:2731-2736, 1995.
2. Shapiro, JD, Milward MJ, Rischin D, et al: Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel. Gynecol Oncol 63:89-93, 1996.
3. Lund B, Hansen OP, Theilade K, et al: Phase II study of gemcitabine (2′,2′-diflorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86:1530-1533, 1994.
4. Perng P-P, Chen YM, Ming-Liu J, et al: Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J Clin Oncol 15:2097-2102, 1997.
5. Manegold C, Herman B, Chemaissani A, et al: Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomized phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 8:525-529, 1997.
6. Rothenberg ML, Moore MJ, Cripps MC, et al: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7:347-353, 1996.
7. Burris HA, Moore MJ, Anderson J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997.
8. Shepherd F: Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small-cell lung cancer: An overview. Anticancer Drugs 6(suppl 6):19-25, 1995.
9. Mosconi AM, Crinò L, Tonato M: Combination therapy with gemcitabine in non-small-cell lung cancer. Eur J Cancer 33(suppl 1):S14-S17, 1997.
10. Lawrence TS, Eisbruch A, Shewach DS: Gemcitabine-mediated radiosensitization. Semin Oncol 24(suppl 7):S7-24-S7-28, 1997.
11. Goor C, Scalliet P, Van Meerbeek J, et al: A phase II study combining gemcitabine with radiotherapy in stage III NSCLC. Ann Oncol 7:101(A481), 1996.
12. Scalliet P, Goor C, Galdermans J, et al: Gemzar with thoracic radiotherapy? A phase II pilot study in chemonaive patients with advanced non-small-cell lung cancer (abstract 1923). Proc Am Soc Clin Oncol 17:499a, 1998.
13. Gregor A, Price A, van der Leest AHD, et al: Phase I study of gemcitabine and radiotherapy in stage III non-small-cell lung cancer (abstract 1953). Proc Am Soc Clin Oncol 18:506a, 1999.
14. Yokes EE, Leopold KA, Herndon JE: A randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy and concomitant chemoradiotherapy forunresectable stage III non-small-cell lung cancer (CALGB Study 9431) (abstract 1771). Proc Am Soc Clin Oncol 18:459a, 1999.